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Abstract
Three meta-analyses have recently been reported on the relationship between choice of
resuscitation fluid and risk of mortality in critically ill patients. The relative risk of death
(1.16–1.19) in two of the meta-analyses was slightly higher in colloid than crystalloid
recipients; however, this observation was not statistically significant. In the third meta-
analysis, 6% (95% confidence interval [CI], 3–9%) pooled excess mortality was
documented in patients receiving albumin for hypovolaemia, burns or hypoalbuminaemia.
The mortality difference in hypovolaemia patients (4%; 95% CI, 0–8%) was not statistically
significant. A variety of serious limitations apply to the three meta-analyses, suggesting that
their findings be interpreted cautiously. More than one-half of the randomized controlled
trials (RCTs) included in the meta-analyses were reported prior to 1990 and hence do not
reflect current practice. Each meta-analysis included only a subset of relevant RCTs, and
therefore the scope of inferences to be drawn from the meta-analytic results is limited. The
meta-analyses combined RCTs that were notably heterogeneous with respect to patient
characteristics, type of illness, administered fluids and physiologic endpoints. Differences in
illness severity, concomitant therapies and fluid management approaches were not taken
into account. Very few of the RCTs were blinded. The meta-analyses do not support the
conclusion that choice of resuscitation fluid is a major determinant of mortality in critically ill
patients, nor do they support changes to current fluid management practice. Changes such
as exclusive reliance on crystalloids would necessitate a reassessment of the goals and
methods of fluid therapy. Since the effect on mortality may be minimal or non-existent, choice
of resuscitation fluid should rest on whether the particular fluid permits the intensive care
unit to provide better patient care.
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Introduction
The recent publication of three meta-analyses [1–3] has
intensified the long-standing debate regarding the merits
of colloids to expand the plasma space in critically ill
patients. Two of these meta-analyses concluded that
excess mortality was associated with the use of colloids
generally [1] and of albumin specifically [2], and proposed
that such use be curtailed outside the context of RCTs.
The third meta-analysis concluded there was no overall
mortality difference associated with colloid versus crystal-
loid resuscitation [3]. Furthermore, due to methodologichttp://ccforum.com/content/4/S2/S26
limitations, evidence-based clinical recommendations
were not deemed to be warranted on the basis of the
meta-analysis [3].
Critical care physicians must now assess what impact, if
any, these meta-analyses should exert upon current clini-
cal practice. This assessment needs to include a close
and rigorous examination of the meta-analyses and the
RCTs underlying them.
Colloid meta-analyses
The systematic review by Schierhout and Roberts [1]
identified 26 RCTs [4–29] encompassing 1622 patients
receiving colloid or crystalloid. Mortality was adopted as
the main outcome measure in the meta-analysis of these
RCTs. Mortality among patients receiving colloid was
found to be greater than that of crystalloid recipients by
4%, with a 95% CI of 0–8%. The corresponding relative
risk of death was 1.19 (95% CI, 0.98–1.45). This differ-
ence was not significant since the 95% CI for relative risk
included 1.
One of the major problems pervading this meta-analysis
was that of heterogeneity among the included RCTs.
Patients with any of various hypovolaemic insults received
any of various colloids or crystalloids at differing concen-
trations. Yet the outcome of hypovolaemia is likely to be
influenced by the cause of the hypovolaemia. There is, fur-
thermore, little basis to postulate that different colloids,
with disparate biochemical properties, will have similar
effects on outcome. There is also little basis that different
crystalloids can be considered similar in their potential
effects on critically ill patients, or that varying colloid and
crystalloid concentrations would have equivalent effects.
Excess mortality was reported in only five of the 19 RCTs
included in the meta-analysis. Two of these, conducted
by the same team of investigators, involved dextran in
hypertonic saline compared with hypotonic saline in
either the prehospital [26] or hospital setting [25]. These
fluid regimens are certainly not representative of current
practice. The report of the prehospital study also does
not make it clear whether haemostasis was secured
before plasma volume expansion. If it was not secured,
then the volume expansion would have increased the risk
of fatal haemorrhage.
The other three RCTs with excess mortality involved
albumin. One death occurred among 14 albumin recipi-
ents in one RCT consisting of the pooled results from two
series [11,17], whereas none of the six crystalloid patients
died. It is difficult, with only a single albumin-associated
death, to infer a meaningful mortality difference, especially
since there were more than twice as many patients in the
albumin group. Another of these RCTs [15] highlights an
additional troublesome source of heterogeneity; namely,
between-group differences in severity of illness. Sepsis
was present in 12/20 (60%) albumin patients compared
with 12/26 (46%) crystalloid recipients in this study of
patients with severe pulmonary insufficiency. The overall
mortality rate for both groups combined was 21/24 (88%)
in the presence of sepsis versus 3/22 (14%) in its
absence. Consequently, the reported excess mortality in
this study can probably be explained by the between-
group disparity in frequency of sepsis rather than by the
choice of resuscitation fluid. The final included RCT with
reported excess mortality [12] compared 2.5% albumin
with Ringer’s lactate in burn patients. Hypo-oncotic 2.5%
albumin is not a routinely used fluid in contemporary
critical care, so again the relevance of this trial to current
practice is uncertain.
The colloid meta-analysis of Choi et al [3] involved 15
RCTs [5,8,10,12–15,20,22,27,30–34] with mortality
data. Results derived from the use of various colloids and
crystalloids in patients with varied hypovolaemic insults
were also combined in this systematic review. The
reported relative risk of death (1.16; 95% CI, 0.85–1.59)
was similar to that found by Schierhout and Roberts [1].
Choi et al [3] were, however, more cautious in their inter-
pretation of the meta-analytic results, concluding that
there was no clear difference between colloids and crys-
talloids with respect to mortality.
Albumin meta-analysis
The Cochrane Injuries Group Albumin Reviewers
(Cochrane Group) performed a meta-analysis of 30 RCTs
[5,6,8–12,14,16,18,21,27,28,30,35–50] comparing admin-
istration of albumin with a regimen of crystalloid or no
albumin in 1419 patients with varied characteristics,
including neonates, and hypovolaemic insults [2]. The
RCTs employed differing concentrations of albumin. Three
categories of indications for albumin were distinguished:
hypovolaemia, burns and hypoalbuminaemia. Overall
excess mortality of 6% (95% CI, 3–9%) was documented
in albumin recipients.
One noteworthy finding of the Cochrane Group meta-
analysis was that, for RCTs of hypovolaemia (the category
of most relevance for critical care physicians), the relative
risk of death after albumin administration (1.46; 95% CI,
0.97–2.22) did not significantly exceed unity. The risk dif-
ference for these RCTs (4%; 95% CI, 0–8%) was also
not statistically significant (Fig. 1). Relative risk was signifi-
cantly above unity for the three included burns trials and
the eight hypoalbuminaemia trials. However, the limited
number of included burns RCTs makes firm conclusions
regarding this indication difficult to reach. The hypo-
albuminaemia trials are also problematic, since hypo-
albuminaemia  per se is less widely accepted currently as
an indication for albumin administration than in past
years. Furthermore, albumin was added to total parenteralCritical Care    Vol 4 Suppl 2 Webb
nutrition fluid in a number of these RCTs, and so there
was potentially increased risk for fungal and bacterial con-
tamination of the fluid and for particulate infusion with
attendant embolic complications.
With respect to the 13 hypovolaemia RCTs considered by
the Cochrane Group, a number of limitations similar to
those of the colloid meta-analyses are apparent. The
RCTs, as already indicated, were heterogeneous with
respect to patient characteristics, hypovolaemic insult and
treatment fluid composition. More than one-half of these
RCTs reported only one or two total deaths [8,10,11,28,
37,38,45]. Finally, the hypovolaemia RCT with by far the
highest relative risk of death [30] entailed a fluid regimen
that would clearly be judged excessive by current stan-
dards. Albumin group patients in this RCT received 12 l
more fluid than their control group counterparts.
Shared limitations of the meta-analyses
The RCTs with mortality data included in all three recent
meta-analyses are listed in Table 1. Two points evident
from inspection of Table 1 are, first, that 26/47 RCTs
(55%) were reported prior to 1990 and thus the meta-
analyses relied heavily upon data unrepresentative of con-
temporary practice. The second point is that there were
extensive differences in the sets of RCTs included in the
three meta-analyses. The aims of the two colloid meta-
analyses were similar; that is, to evaluate in a systematic
fashion the outcomes of colloid administration in critically
ill patients. It is reasonable to suppose that two systematic
reviews with similar aims would identify closely overlap-
ping sets of RCTs. This was not, however, the case.
Twenty of the 30 RCTs involving colloid administration
(67%) were included in one colloid meta-analysis but not
the other.
Furthermore, since albumin is a colloid, both colloid meta-
analyses should arguably have included all the RCTs
encompassed by the albumin meta-analysis. This was also
not the case. Sixteen of the 30 RCTs in the albumin meta-
analysis (53%) were absent from both colloid meta-analy-
ses, and an additional eight (27%) were included in only
one of the two colloid meta-analyses. Only 20% of these
albumin trials were thus shared by all three meta-analyses.
Three albumin RCTs [15,33,34] were also included by one
or both colloid meta-analyses but not the albumin meta-
analysis. These discrepancies in sets of included RCTs
probably reflect, at least partly, differences in selection cri-
teria adopted. It is nevertheless clear that none of the meta-
analyses addressed the totality of relevant evidence.
All three meta-analyses included RCTs that were clearly
heterogeneous from a clinical standpoint. Patients ranged
from neonates to the elderly and differed substantially in
the types of critical illness for which they required fluid
administration. The included RCTs employed disparate
fluids, in varying concentrations, to differing physiological
endpoints. The meta-analyses failed to consider between-
group differences in illness severity or the effects of con-
comitant therapies administered in the intensive care unit,
Figure 1
Mortality risk differences for hypovolaemia RCTs derived from the data of the Cochrane Group meta-analysis [2]. Negative risk difference values
favour albumin, and positive values favour control. Error bars indicate 95% CI.
RCT Year Deaths
Albumin Control
Lowe et al [5] 1977 3/57 3/84
Shah et al [6] 1977 2/9 3/11
Lucas et al [30] 1978 7/27 0/25
Virgilio et al [10] 1979 1/15 1/14
Boutros et al [8] 1979 0/7 2/17
Zetterström and Hedstrand [38] 1981 0/15 1/15
Zetterström [37] 1981 2/9 0/9
Grundmann and Meyer [11] 1982 1/14 0/6
Rackow et al [14] 1983 6/9 6/8
Gallagher et al [16] 1985 0/5 0/5
Nielsen and Engell [18] 1985 0/13 0/13
Prien et al [21] 1990 0/6 0/6
Boldt et al [43] 1993 0/15 0/15
Woods and Kelley [45] 1993 1/37 0/32
Pockaj et al [27] 1994 0/54 0/53
Tølløfsrud et al [28] 1995 0/10 1/10
So et al [49] 1997 7/32 5/31
Woittiez [50] 1998 8/15 4/16
Total 38/349 26/370
Risk Difference (%)
-60 -40 -20 0 20 40 60http://ccforum.com/content/4/S2/S26
Table 1
RCTs with mortality data included in three recent meta-analyses
Meta-analysis
RCT Year Schierhout and Roberts [1] Choi et al [3] Cochrane Group [2]
Bocanegra et al [4] 1966 •
Bland et al [35] 1976 •
Lowe et al [5] 1977 •••
Shah et al [6] 1977 ••
Hall and Sorensen [7] 1978 •
Lucas et al [30] 1978 ••
Boutros et al [8] 1979 •••
Jelenko et al [9] 1979 ••
Virgilio et al [10] 1979 •••
Nilsson et al [36] 1980 •
Moss et al [31]* 1981 •
Zetterström [37] 1981 •
Zetterström and Hedstrand [38] 1981 •
Grundmann and Meyer [11] 1982 ••
Goodwin et al [12] 1983 •••
Modig [13] 1983 ••
Rackow et al [14] 1983 •••
Shires et al [32] 1983 •
Metildi et al [15] 1984 ••
Gallagher et al [16] 1985 ••
Grundmann and Heistermann [17] 1985 •
Nielsen and Engell [18] 1985 ••
Sade et al [33] 1985 •
Karanko [19] 1987 •
Karanko et al [20] 1987 ••
Brown et al [39] 1988 •
Foley et al [40] 1990 •
Prien et al [21] 1990 ••
Dawidson et al [22] 1991 ••
Kanarek et al [41] 1992 •
London et al [34] 1992 •
Wojtysiak et al [42] 1992 •
Younes et al [23] 1992 •
Boldt et al [43] 1993 •
Greenough et al [44] 1993 •
Nagy et al [24] 1993 •
Vassar et al [25] 1993 •
Vassar et al [26] 1993 •
Woods and Kelley [45] 1993 •
Golub et al [46] 1994 •
Pockaj et al [27] 1994 •••
Greenhalgh et al [47] 1995 •
Tølløfsrud et al [28] 1995 ••
Wahba et al [29] 1996 •
Rubin et al [48] 1997 •
So et al [49] 1997 •
Woittiez [50] 1998 •
*This RCT reported on a subset of patients included in Lowe et al [5]. Choi et al [3] elected to consider Moss et al [31] separately. Schierhout and
Roberts [1] and the Cochrane Group [2] considered all the patients, including the subset reported by Moss et al [31], as part of the Lowe et al [5]
RCT.such as circulatory treatment with inotropes, vasopressors
and vasodilators, as well as various protocols for respira-
tory management. The fluid management approach, impor-
tantly, was also not taken into account. Was a fluid
challenge approach adopted? Were fluids administered in
accordance with a priori formulae? Were the endpoints
haemodynamic or biochemical? Did the fluid management
strategy include attempts to minimize oedema? Such
questions were left unaddressed by the meta-analyses.
Although all the included trials were randomized, very few
adopted any form of blinding. The possibility of biased
results therefore cannot be dismissed.
Finally, the between-group differences in mortality reported
by all three meta-analyses were minor. In the absence of
clear-cut fluid-associated differences and in view of their
numerous shared limitations, the meta-analyses do not
provide a compelling basis for critical care physicians to
embrace particular fluid management approaches.
Discussion
The recent meta-analyses have served to reignite the
perennial debate as to the comparative merits of colloids
and crystalloids. Framing the debate in these terms,
however, places the focus on what fluid is used rather
than on how it is used. It is very clear that either crystalloid
or colloid can be harmful if administered in insufficient or
excessive amounts. The key issue is to use fluids skillfully,
taking into account their specific properties and adminis-
tering them in appropriate quantities to haemodynamic
endpoints. Favourable results can be obtained, for
example, by a fluid challenge approach designed to main-
tain the plasma volume at a level that optimizes stroke
output of the heart.
It should also be borne in mind that use of colloids and
crystalloids is by no means mutually exclusive. Indeed,
most patients requiring fluids will probably receive crystal-
loid. The question then becomes whether colloid should
be added to the fluid regimen. The volume administered
will need to be at least three-fold greater than that of
colloid to achieve comparable expansion of the intravascu-
lar compartment if crystalloids are to be relied upon exclu-
sively. Colloids can be administered in smaller volumes
and also serve to increase colloid osmotic pressure. Col-
loids are also retained in the circulation at least for the
5–10-min period needed to perform the measurements of
haemodynamic variables that are essential for implement-
ing a fluid challenge approach. Retention of crystalloid in
the circulation for this minimum period is by no means
assured in patients with extensive vascular leakage.
The supposition that choice of resuscitation fluid might
exert a substantial impact on patient mortality is implicit in
the design of the recent meta-analyses. The fluid-related
differences in mortality documented by the meta-analyses
were relatively small. These findings are unsurprising,
since mortality is most probably affected far more power-
fully by the pathophysiology and severity of the patient’s
illness, the array of other treatments rendered and the
fluid management approach adopted than by the selec-
tion of fluid per se.
The authors of two of the meta-analyses called for RCTs to
be conducted that might resolve the question whether fluid
choice significantly affects mortality [1,2]. The require-
ments for a RCT addressing this issue would, however, be
sobering. If a control group mortality of 20% is assumed
and 97.5% power were desired to detect excess colloid-
associated mortality of at least 4% at the 0.05 a level, then
6584 patients would need to be recruited, or 4611
patients to establish equivalence. The number of patients
would be even higher if lower control group mortality were
assumed. Furthermore, the patients would need to be
similar in type and severity of illness. It would be important
to compare a single colloid with a single crystalloid admin-
istered at the same respective concentrations to the same
endpoints by the same fluid management protocols. Circu-
latory and respiratory management protocols would need
to be comparable. Such a RCT would obviously require the
commitment of daunting healthcare resources. Given the
expectation that choice of fluid may have little or no effect
on mortality, it is highly questionable whether such a RCT
would be a wise investment.
Could the possibility of poorer outcomes with colloids, as
raised by two of the meta-analyses, simply be circum-
vented by switching to crystalloids? Such a change in
fluid management practice would not be trivial. The goals
and methods of fluid therapy would need to be completely
reassessed. The need to tolerate crystalloid-induced
oedema and its corresponding problems would need to
be accepted. Circulatory and respiratory support might
need to be altered. Exclusive reliance on crystalloid might,
for instance, prompt increased use of inotropes and pres-
sors or adjustment of respirator settings to provide a
higher level of positive end-expiratory pressure. Imple-
menting such changes would also require a thorough re-
education process for the entire intensive care unit team, a
process itself not free of risk. Since the available evidence
of colloid-associated excess mortality is far from unequivo-
cal, there is little justification for major changes in fluid
management practice based simply upon the recent meta-
analyses. An issue of greater importance than small or
even non-existent mortality risk differences is, arguably,
whether a particular fluid allows the intensive care unit to
provide better patient care.
Conclusion
The results of recent meta-analyses suggest that the
effect of resuscitation fluid choice on mortality, if any, is
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minor. Furthermore, the meta-analyses need to be inter-
preted with caution due to methodological limitations. The
meta-analyses do not provide a sound rationale for altering
current fluid management practice.
Commentary
Jean-Louis Vincent, MD, PhD: The primary advantages of
colloids are, first, that only a third or less the volume
needs to be administered to achieve the same resuscita-
tion endpoints compared with crystalloids and, second,
that there is less oedema. However, the need to adminis-
ter a larger volume is not necessarily a serious limitation,
and oedema might not be harmful at least in the near
term. Is the presence of interstitial oedema potentially
harmful in terms of oxygen availability to the cells, wound
healing or decubitus ulcers?
Andrew R Webb, MD: It depends on degree. The pres-
ence of some interstitial oedema may not create any
serious problems. It also depends on the type of patient.
Young trauma patients with gunshot wounds may tolerate
massive oedema without adverse sequelae. But in the
elderly patient who may be susceptible to decubitus ulcer
formation or prone to heart failure, oedema should probably
be avoided. The oedema may, for instance, compromise
myocardial function in such patients. Lastly, for sepsis
patients with capillary leakage and massive oedema, it is
probably of great importance that the fluid management
approach be geared toward minimizing oedema.
Uwe Kreimeier, MD: In a recently reported RCT of sepsis
patients receiving normal saline or 5% albumin, the expan-
sion of the extracellular compartment in the albumin group
equalled twice the infused volume [51]. So there appears
to be a fluid volume effect on the interstitium when
albumin is infused in these patients.
Andrew R Webb, MD: That observation has been exten-
sively discussed. There is no doubt that infusing excessive
amounts of colloid can cause interstitial fluid overload.
Moreover, all the colloids are subject to extravasation in
states of capillary leakage such as sepsis. The objective is
to infuse the correct volume of colloid, thereby avoiding
oedema formation, and it is clearly possible to achieve this
objective in many patients. If oedema is kept to a
minimum, it is unlikely that substantial volumes of colloid
will occupy the interstitial space and contribute to fluid
efflux from the plasma space.
William J Sibbald, MD: It is generally possible to achieve
physiologic endpoints more rapidly with colloid than crys-
talloid. This rapidity may, for example, be advantageous in
elderly patients.
The heterogeneity of the RCTs in the meta-analyses really
should be emphasized. A septic patient is clearly unlike an
ischaemia-reperfusion trauma patient. For instance, lym-
phatic flow is much different in a trauma than a sepsis
patient. In sepsis, lymphatic propulsive activity is
depressed, and therefore interstitial fluid is cleared with
greater difficulty. In the trauma patient, this activity is
enhanced. Combining these very different types of patients
in the same meta-analysis is a questionable approach.
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